Allergan, Inc.

Pharmacia & Upjohn Aktiebolag

Allergen, Inc.

Eli Lilly and Company

Scimed Life Systems, Inc.

Other

Pharmacia & Upjohn Ab

Affinity Biotech, Inc.

Pdt, LLC

Robert T Lyons

John T Trogden

James Nienyuan Chang

Scott M Whitcup

Michael R Robinson

Chin-Ming Chang

David H Dillard

Bruce Fieggen

Orest Olejnik

James A Burke

Richard S Graham

Joseph G Vehige

Teresa H Kuan

Scott J Gerondale

Robert S Jordan

Patrick Michael Hughes

Gerald Woodrow DeVries

Robert M Rauker

Werhner C Orilla

Gerald W De Vries

Hongwen Ma Rivers

Scott T Bluni

Gerald W Devries

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions include MAAC solutions or particles present in a therapeutically effective amount, a viscosity-inducing component, and an aqueous carrier component. The compositions have viscosities at about 25&#xb0; C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25&#xb0; C. is in the range of from about 80,000 cps to about 300,000 cps.

High viscosity macromolecular compositions for treating ocular conditions

Compositions, and methods of using such compositions, useful for injection into the posterior segments of human or animal eyes are provided. Such compositions include corticosteroid component-containing particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 300,000 cps. The compositions advantageously suspend the particles for prolonged periods of time.

Pharmaceutical compositions

Viscous formulations and methods of using such compositions, useful for intramuscular and intra-articular injection are provided to treat peripheral conditions. Such compositions can include triamcinolone particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity is in the range of from about 80,000 cps to about 300,000 cps. In a most preferred embodiment, the viscosity is in the range of from about 140,000 cps to about 280,000 cps at a shear rate of 0.1/second at 25&#xb0; C. The compositions advantageously suspend the triamcinolone particles for prolonged periods of time.

Peripherally administered viscous formulations

Ocular implant delivery assemblies are provided which include a cannula having a lumen extending therethrough, a proximal end, a proximal end opening, a distal end, a distal end opening, and a lumen extending through the cannula. A cap is provided having a closed distal end, being in contact with the outer wall of the cannula, and covering the distal end and the distal end opening of the cannula, the cap being structured to allow the distal end and the distal end opening of the cannula to pass through the cap as the cannula is passed into an eye. An ocular implant is located in the lumen. The implant may be sealed in the cannula without the addition of a liquid carrier or it may be contained in a liquid carrier medium in the cannula. The implant may be made up of a number of microparticles having different compositions or different forms. The assembly also includes a sleeve located on the proximal end of the cannula and suitable for coupling the assembly to a syringe containing a pushing gel.

Ocular implant delivery assemblies with distal caps

The present invention provides for compositions for administering a therapeutically effective amount of a therapeutic component. The compositions may include an ophthalmically acceptable carrier component; a therapeutically effective amount of a therapeutic component; and a retention component which may be effective to reduce wettability, induce viscosity, increase muco-adhesion, increase meniscus height on a cornea of an eye and/or increase physical apposition to a cornea of an eye of a composition.

Compositions for delivery of therapeutics into the eyes and methods for making and using same

A drug delivery system (DDS) comprised of segmented biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The segmented implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer, and permit the DDS to have segments that possess individual and different drug release characteristics.

Biodegradable drug delivery system

A biocompatible, sustained release intraocular drug delivery system comprising a protein or polynucleotide therapeutic agent, a polymeric carrier for the therapeutic agent and a long chain fatty alcohol release modifier. The biocompatible, sustained release intraocular drug delivery system can be used to treat an ocular condition.

Sustained release drug delivery systems comprising a water soluble therapeutic agent and a release modifier

Citric acid and conjugate bases thereof are useful for stabilizing stabilized chlorine dioxide in the presence of therapeutically active agents and excipients in a composition. Ophthalmic compositions and methods related thereto are also disclosed herein.

Stabilized compositions comprising a therapeutically active agent and an oxidizing preservative

Anti-angiogenesis compositions, and methods of using such compositions, useful for injection into the vitreous of human eyes are provided. Such compositions can include TKI component solutions or particles present in a therapeutically effective amount, a viscosity inducing component, and an aqueous carrier component. The compositions have viscosities at about 25&#xb0; C. of at least about 10 cps or about 100 cps at a shear rate of 0.1/second. In a preferred embodiment, the viscosity at 25&#xb0; C. is in the range of from about 80,000 cps to about 300,000 cps.

Methods and compositions for intraocular administration to treat ocular conditions

Biocompatible intraocular drug delivery systems in the form of an implant for intraocular administration of siRNA molecules. The drug delivery systems may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions, such as retinal damage, including glaucoma and proliferative vitreoretinopathy among others.

Methods, compositions and drug delivery systems for intraocular delivery of siRNA molecules

Methods for treating a posterior segment of an eye

Stabilized compositions comprising a therapeutically active agent, and an oxidizing preservative

Growing community of inventors

Laguna Hills, CA, United States of America

Robert T Lyons